<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCN</journal-id>
<journal-id journal-id-type="hwp">spjcn</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-title>Journal of Child Neurology</journal-title>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883073812449382</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883073812449382</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Special Issue Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Cardiac Involvement in Hereditary Ataxias</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Moore</surname>
<given-names>Sean</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="aff1-0883073812449382">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Raman</surname>
<given-names>Subha V.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073812449382">1</xref>
<xref ref-type="corresp" rid="corresp1-0883073812449382"/>
</contrib>
<aff id="aff1-0883073812449382"><label>1</label>Division of Cardiovascular Medicine, Ohio State University, Columbus, OH, USA</aff>
</contrib-group>
<contrib-group content-type="issue">
<contrib contrib-type="editor">
<name>
<surname>Maria</surname>
<given-names>Bernard L.</given-names>
</name>
<degrees>MD, MBA</degrees>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0883073812449382">Subha V. Raman, MD, Division of Cardiovascular Medicine, Ohio State University, Columbus, OH 614 293-8963, USA Email: <email>raman.1@osu.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>9</issue>
<issue-title>Special Issue: Childhood Ataxia</issue-title>
<fpage>1174</fpage>
<lpage>1178</lpage>
<history>
<date date-type="received">
<day>13</day>
<month>1</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>4</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Although much attention has been focused on the neurological sequelae of the hereditary ataxias, patients with these conditions also may develop cardiac complications that represent a significant cause of disability and even death. In this article, the authors describe the hereditary ataxias with known cardiac involvement, discuss underlying causes, and review guidelines for screening and treatment. Continued progress will require coordinated clinical trial networks, interdisciplinary care teams, and team science.</p>
</abstract>
<kwd-group>
<kwd>carbohydrate-deficient glycoprotein syndrome type Ia</kwd>
<kwd>Dandy–Walker syndrome</kwd>
<kwd>dilated cardiomyopathy with ataxia</kwd>
<kwd>Friedreich ataxia</kwd>
<kwd>Kearns–Sayre</kwd>
<kwd>spinocerebellar ataxia</kwd>
<kwd>Wilson disease</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Patients with hereditary ataxias typically have a spectrum of neurological manifestations that produce progressive impairment of gait, speech, swallowing, and other complications.<sup>
<xref ref-type="bibr" rid="bibr1-0883073812449382">1</xref>
</sup> There is increasing recognition that cardiac involvement may contribute to death and disability in patients with ataxias, leading to ongoing efforts to define standards for cardiac evaluation and management. In this review, the authors summarize current understanding of cardiac involvement in the hereditary ataxias, and describe possible underlying mechanisms, detection and treatment, and future directions.</p>
<sec id="section1-0883073812449382">
<title>Ataxias With Known Cardiac Involvement</title>
<p>Ataxias known to have cardiac manifestations include Friedreich ataxia, Kearns–Sayre syndrome, carbohydrate-deficient glycoprotein syndrome type Ia, spinocerebellar ataxias, Wilson disease, Dandy–Walker syndrome, and dilated cardiomyopathy with ataxia.</p>
<p>The incidence of Friedreich ataxia is estimated to be 1 in 30 000 people, making it the most common inherited ataxia.<sup>
<xref ref-type="bibr" rid="bibr2-0883073812449382">2</xref>
</sup> Cardiac dysfunction may develop early in the course of the disease. While incidence of cardiac involvement in Friedreich ataxia is high when evaluated at autopsy, clinical severity varies during life. Nonetheless, cardiac disease is now recognized as the leading cause of death in Friedreich ataxia.<sup>
<xref ref-type="bibr" rid="bibr3-0883073812449382">3</xref>
</sup> This potential discrepancy may result from impaired mobility that obscures recognition of cardiac disease if practitioners rely on typical exertional signs and symptoms characteristic of cardiac disease in nonataxic patients.</p>
<p>While Friedreich ataxia classically has been thought to produce hypertrophic cardiomyopathy,<sup>
<xref ref-type="bibr" rid="bibr4-0883073812449382">4</xref>
</sup> more recent studies recognize a spectrum of cardiac phenotypes. The term <italic>concentric remodeling</italic>, a well-recognized form of abnormal cardiac geometry associated with poor outcomes just like frank left ventricular hypertrophy,<sup>
<xref ref-type="bibr" rid="bibr5-0883073812449382">5</xref>
</sup> may better capture the relative increase in wall thickness for the cavity volume in patients with Friedreich ataxia whose absolute left ventricular mass does not meet left ventricular hypertrophy criteria. The authors have similarly found impaired myocardial perfusion reserve using vasodilator stress perfusion imaging, which may reflect impaired energetics at the microvascular level.<sup>
<xref ref-type="bibr" rid="bibr6-0883073812449382">6</xref>
</sup>
</p>
<p>Cardiac conduction abnormalities and cardiomyopathy have long been recognized as complications of Kearns–Sayre syndrome.<sup>
<xref ref-type="bibr" rid="bibr7-0883073812449382">7</xref>
<xref ref-type="bibr" rid="bibr8-0883073812449382"/>–<xref ref-type="bibr" rid="bibr9-0883073812449382">9</xref>
</sup> Clinical sequelae include syncope, congestive heart failure, and cardiac arrest.<sup>
<xref ref-type="bibr" rid="bibr9-0883073812449382">9</xref>,<xref ref-type="bibr" rid="bibr10-0883073812449382">10</xref>
</sup>
</p>
<p>In carbohydrate-deficient glycoprotein syndrome type Ia, cardiac manifestations have ranged from hypertrophic cardiomyopathy<sup>
<xref ref-type="bibr" rid="bibr11-0883073812449382">11</xref>
</sup> to pericardial effusion and tamponade.<sup>
<xref ref-type="bibr" rid="bibr12-0883073812449382">12</xref>
</sup> Conotruncal abnormalities have also been reported.<sup>
<xref ref-type="bibr" rid="bibr13-0883073812449382">13</xref>
</sup> Among all congenital disorders of glycosylation, mean age of onset of cardiac involvement is 5 months.<sup>
<xref ref-type="bibr" rid="bibr14-0883073812449382">14</xref>
</sup> About 20% of patients with carbohydrate-deficient glycoprotein syndrome type Ia die within the first year of life, often resulting from serious cardiac complications.<sup>
<xref ref-type="bibr" rid="bibr14-0883073812449382">14</xref>
</sup> In one study of children with congenital disorders of glycosylation, 2 out of 5 with carbohydrate-deficient glycoprotein syndrome type Ia died as the result of cardiac complications before the age of 3 months.<sup>
<xref ref-type="bibr" rid="bibr14-0883073812449382">14</xref>
</sup>
</p>
<p>Spinocerebellar ataxia types 1, 2, and 3 can produce cardiovascular abnormalities, particularly abnormal heart rate variability.<sup>
<xref ref-type="bibr" rid="bibr15-0883073812449382">15</xref>
</sup> Autonomic disturbances have been most commonly reported.<sup>
<xref ref-type="bibr" rid="bibr16-0883073812449382">16</xref>,<xref ref-type="bibr" rid="bibr17-0883073812449382">17</xref>
</sup> While one report describes a case of sudden cardiac death in a patient with “spinocerebellar ataxia,”<sup>
<xref ref-type="bibr" rid="bibr18-0883073812449382">18</xref>
</sup> lack of molecular diagnosis and clinical similarity to Friedreich ataxia make it difficult to know whether spinocerebellar ataxia was truly the underlying disorder.</p>
<p>Cardiac abnormalities in Wilson disease, a disorder of copper metabolism, include concentric remodeling and supraventricular tachycardia.<sup>
<xref ref-type="bibr" rid="bibr19-0883073812449382">19</xref>
</sup> Pathology suggests there can be myocardial inflammation and interstitial fibrosis.<sup>
<xref ref-type="bibr" rid="bibr20-0883073812449382">20</xref>
</sup> Most electrocardiographic abnormalities in patients with Wilson disease are subclinical, but arrhythmias demonstrated on electrocardiography may portend increased risk of cardiac death.<sup>
<xref ref-type="bibr" rid="bibr21-0883073812449382">21</xref>
</sup>
</p>
<p>Dandy–Walker malformations can be associated with congenital heart disease, including ventricular septal defects, patent ductus arteriosus, transposition of the great arteries, and pulmonic stenosis.<sup>
<xref ref-type="bibr" rid="bibr22-0883073812449382">22</xref>
</sup> Systemic anomalies associated with Dandy–Walker malformations (excluding central nervous system malformations) occur in around 25% of cases, according to Hart and colleagues.<sup>
<xref ref-type="bibr" rid="bibr23-0883073812449382">23</xref>
</sup> Patients with Dandy–Walker malformations with cardiac involvement often present early with symptoms of cardiac insufficiency (in the first year of life), and prognosis is dependent on the nature and severity of the specific cardiac malformation.<sup>
<xref ref-type="bibr" rid="bibr24-0883073812449382">24</xref>,<xref ref-type="bibr" rid="bibr25-0883073812449382">25</xref>
</sup>
</p>
<p>Patients with dilated cardiomyopathy with ataxia can present with cardiac disease before the age of 3, including sequelae of dilated cardiomyopathy and long QT syndrome.<sup>
<xref ref-type="bibr" rid="bibr26-0883073812449382">26</xref>
</sup> Of patients, 70% die of progressive cardiac failure or sudden cardiac death, often within the first few years of life.<sup>
<xref ref-type="bibr" rid="bibr26-0883073812449382">26</xref>,<xref ref-type="bibr" rid="bibr27-0883073812449382">27</xref>
</sup>
</p>
<p>Juvenile GM2 gangliosidosis has also been reported to cause autonomic dysfunction, though cardiovascular sequelae are not typically apparent.<sup>
<xref ref-type="bibr" rid="bibr28-0883073812449382">28</xref>
</sup>
</p>
</sec>
<sec id="section2-0883073812449382">
<title>Underlying Mechanisms of Cardiac Involvement in the Ataxias</title>
<p>Friedreich ataxia results most commonly from a GAA triplet expansion in the first intron of the frataxin gene on chromosome 9q21.11, and occasionally as a result of point mutations. Frataxin is an essential and highly expressed protein that functions in mitochondrial iron homeostasis.<sup>
<xref ref-type="bibr" rid="bibr29-0883073812449382">29</xref>
</sup> In a cellular environment where frataxin is diminished or absent, free iron accumulates in the mitochondria, and the creation of iron-sulfur prosthetic groups is decreased, leading to decreased energy production via the electron transport chain as well as free-radical generation and oxidant stress via electron loss.<sup>
<xref ref-type="bibr" rid="bibr30-0883073812449382">30</xref>
<xref ref-type="bibr" rid="bibr31-0883073812449382"/>
<xref ref-type="bibr" rid="bibr32-0883073812449382"/>–<xref ref-type="bibr" rid="bibr33-0883073812449382">33</xref>
</sup> This reduced energy production because of frataxin deficits has severe effects on cardiomyocytes, whose sarcomeres lack adequate levels of adenosine triphosphate for normal contractile function. A disruption of the normal mitochondria-to-sarcomere ratio is observed.<sup>
<xref ref-type="bibr" rid="bibr34-0883073812449382">34</xref>
</sup> How frataxin deficiency translates to concentric remodeling, however, remains unknown. It has been postulated that impaired energy-dependent vasodilatation of the coronary microcirculation contributes,<sup>
<xref ref-type="bibr" rid="bibr6-0883073812449382">6</xref>
</sup> as it does in hypertrophic cardiomyopathies resulting from sarcomeric mutations.<sup>
<xref ref-type="bibr" rid="bibr35-0883073812449382">35</xref>
</sup> The authors have also identified features of the metabolic syndrome in addition to the long-known ∼10% incidence of frank diabetes in patients with Friedreich ataxia.<sup>
<xref ref-type="bibr" rid="bibr36-0883073812449382">36</xref>
</sup> In several studies, increased number of GAA repeats has correlated with cardiomyopathy severity and earlier onset.</p>
<p>Cardiac involvement in Kearns–Sayre syndrome is often associated with large-scale mitochondrial DNA deletions; between 15% and 40% of a patient’s mitochondrial DNA within the heart muscle can be lost.<sup>
<xref ref-type="bibr" rid="bibr10-0883073812449382">10</xref>
</sup> These deletions may be the result of a deficiency in the p53R2 subunit of ribonucleotide reductase, caused by missense mutations in its nuclear encoding DNA region, RRM2B.<sup>
<xref ref-type="bibr" rid="bibr37-0883073812449382">37</xref>
</sup> Deletions beginning at a certain base pair number of mitochondrial DNA called the “hot spot”<sup>
<xref ref-type="bibr" rid="bibr38-0883073812449382">38</xref>
</sup> are thought to be the cause of cardiac conduction defects in patients with Kearns–Sayre syndrome evaluated in correlation studies.<sup>
<xref ref-type="bibr" rid="bibr39-0883073812449382">39</xref>
</sup> Though the exact mechanism of how conduction defects manifest is unknown, many biopsy studies performed with electron microscopy on patients with Kearns–Sayre syndrome who have conduction defects have shown abnormal mitochondrial structure, number, and placement within the myocardial cells. These morphological effects on the conducting tissue of the heart are thought to cause conduction defects such as left anterior hemiblock, right bundle branch block, and left bundle branch block, often progressing toward complete atrioventricular block in patients with Kearns–Sayre syndrome.<sup>
<xref ref-type="bibr" rid="bibr9-0883073812449382">9</xref>
</sup> It is hypothesized that the metabolic and morphological anomalies initially mostly affect conduction tissue, although in later years contractile tissue can be affected as well, leading to clinical myocardial disease.<sup>
<xref ref-type="bibr" rid="bibr9-0883073812449382">9</xref>
</sup>
</p>
<p>Carbohydrate-deficient glycoprotein syndrome type Ia, also referred to as phosphomannomutase 2 deficiency, is caused by a defect in the second step in the synthesis of guanosine diphosphate-mannose. Deficiency of guanosine diphosphate-mannose induces hypoglycosylation of serum proteins, membranous glycoproteins, and lysosomal enzymes.<sup>
<xref ref-type="bibr" rid="bibr40-0883073812449382">40</xref>
</sup> Gehrmann and colleagues<sup>
<xref ref-type="bibr" rid="bibr14-0883073812449382">14</xref>
</sup> have suggested that the cardiomyopathy seen in carbohydrate-deficient glycoprotein syndrome type Ia arises from hypoglycosylation of dystrophin-associated glycoproteins in the sarcolemmal plasma membrane. The authors suggest that the alteration in structure of these proteins affects signal transduction pathways and calcium homeostasis, leading to myocardial disease. An embryological mechanism has been proposed for conotruncal heart defects in carbohydrate-deficient glycoprotein syndrome type Ia patients by Romano and colleagues,<sup>
<xref ref-type="bibr" rid="bibr13-0883073812449382">13</xref>
</sup> wherein abnormal neural crest cell migration causes cardiac anomalies. Many cell adhesion molecules, transcription factors, growth factors, and their receptors are involved in neural crest cell migration.<sup>
<xref ref-type="bibr" rid="bibr41-0883073812449382">41</xref>
</sup> The authors believe that hypoglycosylation of glycoproteins involved in this process because of phosphomannomutase 2 deficiency creates abnormal neural crest cell migration, leading to congenital heart anomalies such as conotruncal heart defects.<sup>
<xref ref-type="bibr" rid="bibr13-0883073812449382">13</xref>
</sup>
</p>
<p>The etiology of Wilson disease has been mapped to mutations in a gene on chromosome 13 encoding the ATP7B membrane protein, which resides in hepatocytes in the trans-Golgi network.<sup>
<xref ref-type="bibr" rid="bibr42-0883073812449382">42</xref>,<xref ref-type="bibr" rid="bibr43-0883073812449382">43</xref>
</sup> Alterations in this protein causes copper accumulation first in the liver; when the liver’s capacity to store copper is exhausted, copper is released into the circulation and deposits in other tissues, including heart muscle.<sup>
<xref ref-type="bibr" rid="bibr44-0883073812449382">44</xref>
</sup> Hlubocka and colleagues<sup>
<xref ref-type="bibr" rid="bibr19-0883073812449382">19</xref>
</sup> suggest the pathophysiology of cardiac involvement in Wilson disease is similar to that of the liver, wherein generation of free radicals because of excess intra- and extracardiac copper accumulation causes an atrophic response in cardiac muscle. Further studies to support this hypothesis are needed.</p>
<p>The exact pathophysiology by which the Dandy–Walker malformation occurs is still unknown. The high incidence of cardiac anomalies in patients with Dandy–Walker malformation suggests an embryonic developmental linkage. However, the available medical literature provides no direct evidence of the mechanistic underpinnings of cardiac disease in these patients.</p>
<p>Dilated cardiomyopathy with ataxia is an autosomal recessive disorder that arises from a point mutation in the nuclear <italic>DNAJC19</italic> gene.<sup>
<xref ref-type="bibr" rid="bibr26-0883073812449382">26</xref>
</sup> This gene encodes a chaperone protein likely located in the inner mitochondrial membrane involved in the folding of newly synthesized proteins and in prevention of abnormal folding and aggregation of proteins during cellular conditions of stress.<sup>
<xref ref-type="bibr" rid="bibr26-0883073812449382">26</xref>
</sup> It has been suggested that disruption in mitochondrial protein import from the cytosol caused by the point mutation in <italic>DNAJC19</italic> leads to aerobic metabolic deficiency, which causes the dilated cardiomyopathy.<sup>
<xref ref-type="bibr" rid="bibr27-0883073812449382">27</xref>
</sup> Further preclinical studies may better inform pathophysiologic mechanisms linking genotype with cardiac phenotype.</p>
</sec>
<sec id="section3-0883073812449382">
<title>Guidelines for Cardiac Screening and Treatment</title>
<p>For ataxic disorders where cardiomyopathy is known to be the leading cause of death, early diagnosis is possible. Electrocardiography is widely and readily available, and often shows nonspecific ST and T-wave abnormalities. Electrocardiographic abnormalities are seen in 75% to 100% of patients with Friedreich ataxia, with nonspecific repolarization abnormalities occurring commonly.<sup>
<xref ref-type="bibr" rid="bibr45-0883073812449382">45</xref>,<xref ref-type="bibr" rid="bibr46-0883073812449382">46</xref>
</sup> Echocardiography identifies concentric left ventricular hypertrophy and diastolic dysfunction in 62% of patients with Friedreich ataxia.<sup>
<xref ref-type="bibr" rid="bibr47-0883073812449382">47</xref>
</sup> What one does at the initial detection of myocardial involvement remains uncertain, and the rare nature of the disease leads to highly variable practice across a variety of community versus tertiary care centers. In the absence of curative approaches, the authors are left with applying guidelines developed for other forms of myocardial disease.<sup>
<xref ref-type="bibr" rid="bibr48-0883073812449382">48</xref>
</sup> Most commonly used are angiotensin-converting enzyme inhibitors and beta-blocking drugs, although no randomized controlled trial or even registry has been conducted using such agents in Friedreich ataxia cardiomyopathy.</p>
<p>Antioxidant therapies to protect against mitochondrial damage to the heart remain appealing. While clinical trials to date have not demonstrated a sustained benefit of antioxidant or any other pharmaceutical therapy in the treatment of Friedreich ataxia cardiomyopathy,<sup>
<xref ref-type="bibr" rid="bibr49-0883073812449382">49</xref>
</sup> Myers and colleagues<sup>
<xref ref-type="bibr" rid="bibr50-0883073812449382">50</xref>
</sup> importantly point out the potential major confounding effect of nonprescription antioxidant use in such trials. Bone-marrow-derived mesenchymal stem cells increase frataxin production and decrease oxidative stress in fibroblast mitochondria from patients with Friedreich’s ataxia in vitro;<sup>
<xref ref-type="bibr" rid="bibr51-0883073812449382">51</xref>
</sup> in vivo studies are needed.</p>
<p>Given the conduction system disease in Kearns–Sayre syndrome, it would seem prudent to perform early and routine electrocardiographic screening in these patients. Affected or at-risk family members can also be readily evaluated with this simple tool.<sup>
<xref ref-type="bibr" rid="bibr10-0883073812449382">10</xref>
</sup> Because of the risk of sudden death from atrioventricular block in patients with Kearns–Sayre syndrome, consideration of pacemaker implantation is recommended with or without clinical symptoms based on detection of high-grade conduction system disease by electrocardiography.<sup>
<xref ref-type="bibr" rid="bibr10-0883073812449382">10</xref>
</sup>
</p>
<p>Little has been written regarding cardiac treatment in patients with Dandy–Walker malformation, as most of the medical literature focuses on the neurological effects of the disease. Sparkes and colleagues<sup>
<xref ref-type="bibr" rid="bibr27-0883073812449382">27</xref>
</sup> advocate routine electrocardiographic and echocardiographic assessment in patients with dilated cardiomyopathy with ataxia regardless of whether clinical symptoms are present because of the high incidence of cardiac complications associated with the disease. Better understanding of the pathogenesis of dilated cardiomyopathy in this disorder may identify potential targets for preventive therapy.<sup>
<xref ref-type="bibr" rid="bibr27-0883073812449382">27</xref>
</sup>
</p>
<p>Symptomatic and presymptomatic Wilson disease patients are typically treated with copper chelating agents that bind free copper and reduce mitochondrial damage in affected organs. Though these agents are known to have beneficial effects on hepatocytes, remarkably little has been reported on the utility of agents such as <sc>d</sc>-penicillamine once myocardial disease has ensued. The impact of liver transplantation on cardiomyopathy in Wilson disease remains poorly characterized.</p>
<p>Bedside evaluation of volume status is one of the most important yet perhaps least appreciated components of the clinical exam of any patient with cardiac disease. Limitations imposed by body habitus and chest wall deformities make the inspection of the jugular venous pressure challenging in patients with many forms of neuromuscular disease, including the hereditary ataxias. The risks of not paying adequate attention to intravascular volume include poor tolerance of indiscriminate volume overload in patients with diastolic abnormalities, such as the patient with Friedreich ataxia who is undergoing noncardiac surgery. Similarly, excess volume depletion may exacerbate low-cardiac-output symptoms.</p>
</sec>
<sec id="section4-0883073812449382">
<title>Future Directions</title>
<p>A review of the literature reveals obvious gaps in the collective knowledge of cardiac involvement in the hereditary ataxias, particularly regarding etiology, pathophysiology, optimal diagnostic strategies, and treatment. The rarity of these disorders coupled with a predominant focus on neurological complications are ongoing challenges that can be overcome with recognition and strategic planning. Coordinated clinical trial networks, interdisciplinary care teams, and team science in preclinical studies are absolutely required for any progress to be made. With such efforts, cardiac involvement in the hereditary ataxias can be better recognized and treated, reducing a major source of morbidity and mortality for these patients.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The article was presented at the Neurobiology of Disease in Children Symposium: Childhood Ataxia, in conjunction with the 40th Annual Meeting of the Child Neurology Society, Savannah, Georgia, October 26, 2011. The authors thank Melanie Fridl Ross, MSJ, ELS, for editing assistance.</p>
</ack>
<fn-group>
<fn fn-type="other" id="fn1-0883073812449382">
<label>Author Contributions</label>
<p>SM developed the manuscript outline. SVR performed the literature search and initial draft and SM performed critical revisions of the entire article.</p>
</fn>
<fn fn-type="conflict" id="fn2-0883073812449382">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-0883073812449382">
<label>Funding</label>
<p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Supported by grants from the National Institute of Neurological Disorders and Stroke (5R13NS040925-15), the National Institutes of Health Office of Rare Disease Research, the Child Neurology Society, and the National Ataxia Foundation. Supported by grants from the National Institutes of Health (2R13NS040925-14 Revised), the National Heart Lung and Blood Institute (R01-HL095563),the National Institutes of Health Office of Rare Diseases Research, the Child Neurology Society, and the National Ataxia Foundation.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883073812449382">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klockgether</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Paulson</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Milestones in ataxia</article-title>. <source>Mov Disord</source>. <year>2011</year>;<volume>26</volume>(<issue>6</issue>):<fpage>1134</fpage>–<lpage>1141</lpage>.</citation>
</ref>
<ref id="bibr2-0883073812449382">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schols</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Amoiridis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Przuntek</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Epplen</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Epplen</surname>
<given-names>C.</given-names>
</name>
</person-group> <article-title>Friedreich’s ataxia. Revision of the phenotype according to molecular genetics</article-title>. <source>Brain</source>. <year>1997</year>;<volume>120</volume>(<issue>12</issue>):<fpage>2131</fpage>–<lpage>2140</lpage>.</citation>
</ref>
<ref id="bibr3-0883073812449382">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsou</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Paulsen</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Lagedrost</surname>
<given-names>SJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Mortality in Friedreich ataxia</article-title>. <source>J Neurol Sci</source>. <year>2011</year>;<volume>307</volume>(<issue>1-2</issue>):<fpage>46</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr4-0883073812449382">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harding</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Hewer</surname>
<given-names>RL</given-names>
</name>
</person-group>. <article-title>The heart disease of Friedreich’s ataxia: a clinical and electrocardiographic study of 115 patients, with an analysis of serial electrocardiographic changes in 30 cases</article-title>. <source>QJM</source>. <year>1983</year>;<volume>52</volume>(<issue>208</issue>):<fpage>489</fpage>–<lpage>502</lpage>.</citation>
</ref>
<ref id="bibr5-0883073812449382">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Artham</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Lavie</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Milani</surname>
<given-names>RV</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Verma</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ventura</surname>
<given-names>HO</given-names>
</name>
</person-group>. <article-title>Clinical impact of left ventricular hypertrophy and implications for regression</article-title>. <source>Prog Cardiovasc Dis</source>. <year>2009</year>;<volume>52</volume>(<issue>2</issue>):<fpage>153</fpage>–<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr6-0883073812449382">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raman</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Phatak</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hoyle</surname>
<given-names>JC</given-names>
</name>
<etal/>
</person-group>. <article-title>Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome</article-title>. <source>Eur Heart J</source>. <year>2011</year>;<volume>32</volume>(<issue>5</issue>):<fpage>561</fpage>–<lpage>567</lpage>.</citation>
</ref>
<ref id="bibr7-0883073812449382">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Channer</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Channer</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Rees</surname>
<given-names>JR</given-names>
</name>
</person-group>. <article-title>Cardiomyopathy in the Kearns–Sayre syndrome</article-title>. <source>Br Heart J</source>. <year>1988</year>;<volume>59</volume>(<issue>4</issue>):<fpage>486</fpage>–<lpage>490</lpage>.</citation>
</ref>
<ref id="bibr8-0883073812449382">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hubner</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gokel</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Pongratz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Johannes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>JW</given-names>
</name>
</person-group>. <article-title>Fatal mitochondrial cardiomyopathy in Kearns–Sayre syndrome</article-title>. <source>Virchows Arch A Pathol Anat Histopathol</source>. <year>1986</year>;<volume>408</volume>(<issue>6</issue>):<fpage>611</fpage>–<lpage>621</lpage>.</citation>
</ref>
<ref id="bibr9-0883073812449382">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Charles</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Holt</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kay</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Epstein</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Rees</surname>
<given-names>JR</given-names>
</name>
</person-group>. <article-title>Myocardial ultrastructure and the development of atrioventricular block in Kearns–Sayre syndrome</article-title>. <source>Circulation</source>. <year>1981</year>;<volume>63</volume>(<issue>1</issue>):<fpage>214</fpage>–<lpage>219</lpage>.</citation>
</ref>
<ref id="bibr10-0883073812449382">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>DL</given-names>
</name>
</person-group>. <article-title>Kearns–Sayre syndrome: a case report and review of cardiovascular complications</article-title>. <source>Pacing Clin Electrophysiol</source>. <year>2005</year>;<volume>28</volume>(<issue>5</issue>):<fpage>454</fpage>–<lpage>457</lpage>.</citation>
</ref>
<ref id="bibr11-0883073812449382">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clayton</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Winchester</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Keir</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Hypertrophic obstructive cardiomyopathy in a neonate with the carbohydrate-deficient glycoprotein syndrome</article-title>. <source>J Inherit Metab Dis</source>. <year>1992</year>;<volume>15</volume>(<issue>6</issue>):<fpage>857</fpage>–<lpage>861</lpage>.</citation>
</ref>
<ref id="bibr12-0883073812449382">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grunewald</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia)</article-title>. <source>Biochim Biophys Acta</source>. <year>2009</year>;<volume>1792</volume>(<issue>9</issue>):<fpage>827</fpage>–<lpage>834</lpage>.</citation>
</ref>
<ref id="bibr13-0883073812449382">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bajolle</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Valayannopoulos</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Conotruncal heart defects in three patients with congenital disorder of glycosylation type Ia (CDG Ia)</article-title>. <source>J Med Genet</source>. <year>2009</year>;<volume>46</volume>(<issue>4</issue>):<fpage>287</fpage>–<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr14-0883073812449382">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gehrmann</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sohlbach</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Linnebank</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Cardiomyopathy in congenital disorders of glycosylation</article-title>. <source>Cardiol Young</source>. <year>2003</year>;<volume>13</volume>(<issue>4</issue>):<fpage>345</fpage>–<lpage>351</lpage>.</citation>
</ref>
<ref id="bibr15-0883073812449382">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pradhan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yashavantha</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Pal</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Sathyaprabha</surname>
<given-names>TN</given-names>
</name>
</person-group>. <article-title>Spinocerebellar ataxias type 1, 2 and 3: a study of heart rate variability</article-title>. <source>Acta Neurol Scand</source>. <year>2008</year>;<volume>117</volume>(<issue>5</issue>):<fpage>337</fpage>–<lpage>342</lpage>.</citation>
</ref>
<ref id="bibr16-0883073812449382">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Joanna</surname>
<given-names>G</given-names>
</name>
<name>
<surname>De Rosa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Salvatore</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Autonomic nervous system abnormalities in spinocerebellar ataxia type 2: a cardiovascular neurophysiologic study</article-title>. <source>J Neurol Sci</source>. <year>2008</year>;<volume>275</volume>(<issue>1-2</issue>):<fpage>60</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr17-0883073812449382">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montes-Brown</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Machado</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Estevez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carricarte</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Velazquez-Perez</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Autonomic dysfunction in presymptomatic spinocerebellar ataxia type-2</article-title>. <source>Acta Neurol Scand</source>. <year>2011</year>;<volume>125</volume>(<issue>1</issue>):<fpage>24</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr18-0883073812449382">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fineschi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Panarese</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zeppa</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Sudden cardiac death in a case of spinocerebellar ataxia (Friedreich-like phenotype)</article-title>. <source>Int J Cardiol</source>. <year>2006</year>;<volume>106</volume>(<issue>3</issue>):<fpage>424</fpage>–<lpage>425</lpage>.</citation>
</ref>
<ref id="bibr19-0883073812449382">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hlubocka</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Marecek</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Linhart</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Cardiac involvement in Wilson disease</article-title>. <source>J Inherit Metab Dis</source>. <year>2002</year>;<volume>25</volume>(<issue>4</issue>):<fpage>269</fpage>–<lpage>277</lpage>.</citation>
</ref>
<ref id="bibr20-0883073812449382">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lorincz</surname>
<given-names>MT</given-names>
</name>
</person-group>. <article-title>Neurologic Wilson’s disease</article-title>. <source>Ann N Y Acad Sci</source>. <year>2010</year>;<volume>1184</volume>:<fpage>173</fpage>–<lpage>187</lpage>.</citation>
</ref>
<ref id="bibr21-0883073812449382">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuan</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Cardiac Wilson’s disease</article-title>. <source>Chest</source>. <year>1987</year>;<volume>91</volume>(<issue>4</issue>):<fpage>579</fpage>–<lpage>583</lpage>.</citation>
</ref>
<ref id="bibr22-0883073812449382">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olson</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Halpe</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Spataro</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Dandy–Walker malformation and associated cardiac anomalies</article-title>. <source>Childs Brain</source>. <year>1981</year>;<volume>8</volume>(<issue>3</issue>):<fpage>173</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr23-0883073812449382">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hart</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Malamud</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>WG</given-names>
</name>
</person-group>. <article-title>The Dandy–Walker syndrome: a clinicopathological study based on 28 cases</article-title>. <source>Neurology</source>. <year>1972</year>;<volume>22</volume>(<issue>8</issue>):<fpage>771</fpage>–<lpage>780</lpage>.</citation>
</ref>
<ref id="bibr24-0883073812449382">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yarom</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fried</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Hypertrophy of heart with outflow tract obstruction and myocardial necrosis in an infant with multiple congenital malformations</article-title>. <source>Br Heart J</source>. <year>1971</year>;<volume>33</volume>(<issue>3</issue>):<fpage>420</fpage>–<lpage>422</lpage>.</citation>
</ref>
<ref id="bibr25-0883073812449382">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sautreaux</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Giroud</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dauvergne</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nivelon</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Thierry</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Dandy–Walker malformation associated with occipital meningocele and cardiac anomalies: a rare complex embryologic defect</article-title>. <source>J Child Neurol</source>. <year>1986</year>;<volume>1</volume>(<issue>1</issue>):<fpage>64</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr26-0883073812449382">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davey</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Parboosingh</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>McLeod</surname>
<given-names>DR</given-names>
</name>
<etal/>
</person-group>. <article-title>Mutation of DNAJC19, a human homologue of yeast inner mitochondrial membrane co-chaperones, causes DCMA syndrome, a novel autosomal recessive Barth syndrome-like condition</article-title>. <source>J Med Genet</source>. <year>2006</year>;<volume>43</volume>(<issue>5</issue>):<fpage>385</fpage>–<lpage>393</lpage>.</citation>
</ref>
<ref id="bibr27-0883073812449382">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sparkes</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Patton</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bernier</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Cardiac features of a novel autosomal recessive dilated cardiomyopathic syndrome due to defective importation of mitochondrial protein</article-title>. <source>Cardiol Young</source>. <year>2007</year>;<volume>17</volume>(<issue>2</issue>):<fpage>215</fpage>–<lpage>217</lpage>.</citation>
</ref>
<ref id="bibr28-0883073812449382">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salman</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Midroni</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Waxman</surname>
<given-names>MB</given-names>
</name>
</person-group>. <article-title>Peripheral and autonomic nervous system involvement in chronic GM2-gangliosidosis</article-title>. <source>J Inherit Metab Dis</source>. <year>2001</year>;<volume>24</volume>(<issue>1</issue>):<fpage>65</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr29-0883073812449382">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Whitnall</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suryo Rahmanto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ponka</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>DR</given-names>
</name>
</person-group>. <article-title>Elucidation of the mechanism of mitochondrial iron loading in Friedreich’s ataxia by analysis of a mouse mutant</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2009</year>;<volume>106</volume>(<issue>38</issue>):<fpage>16381</fpage>–<lpage>16386</lpage>.</citation>
</ref>
<ref id="bibr30-0883073812449382">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rotig</surname>
<given-names>A</given-names>
</name>
<name>
<surname>de Lonlay</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chretien</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia</article-title>. <source>Nat Genet</source>. <year>1997</year>;<volume>17</volume>(<issue>2</issue>):<fpage>215</fpage>–<lpage>217</lpage>.</citation>
</ref>
<ref id="bibr31-0883073812449382">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lodi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>JL</given-names>
</name>
<etal/>
</person-group>. <article-title>Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>1999</year>;<volume>96</volume>(<issue>20</issue>):<fpage>11492</fpage>–<lpage>11495</lpage>.</citation>
</ref>
<ref id="bibr32-0883073812449382">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandolfo</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Iron and Friedreich ataxia</article-title>. <source>J Neural Transm Suppl</source>. <year>2006</year>(<issue>70</issue>):<fpage>143</fpage>–<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr33-0883073812449382">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schulz</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Dehmer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schols</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Oxidative stress in patients with Friedreich ataxia</article-title>. <source>Neurology</source>. <year>2000</year>;<volume>55</volume>(<issue>11</issue>):<fpage>1719</fpage>–<lpage>1721</lpage>.</citation>
</ref>
<ref id="bibr34-0883073812449382">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Payne</surname>
<given-names>RM</given-names>
</name>
</person-group>. <article-title>The heart in Friedreich’s ataxia: basic findings and clinical implications</article-title>. <source>Prog Pediatr Cardiol</source>. <year>2011</year>;<volume>31</volume>(<issue>2</issue>):<fpage>103</fpage>–<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr35-0883073812449382">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olivotto</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Girolami</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Sciagra</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations</article-title>. <source>J Am Coll Cardiol</source>. <year>2011</year>;<volume>58</volume>(<issue>8</issue>):<fpage>839</fpage>–<lpage>848</lpage>.</citation>
</ref>
<ref id="bibr36-0883073812449382">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandolfo</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Friedreich ataxia</article-title>. <source>Arch Neurol</source>. <year>2008</year>;<volume>65</volume>(<issue>10</issue>):<fpage>1296</fpage>–<lpage>1303</lpage>.</citation>
</ref>
<ref id="bibr37-0883073812449382">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitceathly</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Fassone</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Taanman</surname>
<given-names>JW</given-names>
</name>
<etal/>
</person-group>. <article-title>Kearns–Sayre syndrome caused by defective R1/p53R2 assembly</article-title>. <source>J Med Genet</source>. <year>2011</year>;<volume>48</volume>(<issue>9</issue>):<fpage>610</fpage>–<lpage>617</lpage>.</citation>
</ref>
<ref id="bibr38-0883073812449382">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moraes</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>DiMauro</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zeviani</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns–Sayre syndrome</article-title>. <source>N Engl J Med</source>. <year>1989</year>;<volume>320</volume>(<issue>20</issue>):<fpage>1293</fpage>–<lpage>1299</lpage>.</citation>
</ref>
<ref id="bibr39-0883073812449382">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miyata</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Cardiac involvement in mitochondrial diseases: a study on 17 patients with documented mitochondrial DNA defects</article-title>. <source>Circulation</source>. <year>1995</year>;<volume>91</volume>(<issue>4</issue>):<fpage>955</fpage>–<lpage>961</lpage>.</citation>
</ref>
<ref id="bibr40-0883073812449382">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaeken</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Congenital disorders of glycosylation</article-title>. <source>Ann N Y Acad Sci</source>. <year>2010</year>;<volume>1214</volume>:<fpage>190</fpage>–<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr41-0883073812449382">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maschhoff</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Baldwin</surname>
<given-names>HS</given-names>
</name>
</person-group>. <article-title>Molecular determinants of neural crest migration</article-title>. <source>Am J Med Genet</source>. <year>2000</year>;<volume>97</volume>(<issue>4</issue>):<fpage>280</fpage>–<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr42-0883073812449382">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bull</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Rommens</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Forbes</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>DW</given-names>
</name>
</person-group>. <article-title>The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene</article-title>. <source>Nat Genet</source>. <year>1993</year>;<volume>5</volume>(<issue>4</issue>):<fpage>327</fpage>–<lpage>337</lpage>.</citation>
</ref>
<ref id="bibr43-0883073812449382">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanzi</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Petrukhin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chernov</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene</article-title>. <source>Nat Genet</source>. <year>1993</year>;<volume>5</volume>(<issue>4</issue>):<fpage>344</fpage>–<lpage>350</lpage>.</citation>
</ref>
<ref id="bibr44-0883073812449382">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferenci</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Pathophysiology and clinical features of Wilson disease</article-title>. <source>Metab Brain Dis</source>. <year>2004</year>;<volume>19</volume>(<issue>3-4</issue>):<fpage>229</fpage>–<lpage>239</lpage>.</citation>
</ref>
<ref id="bibr45-0883073812449382">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harding</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Hewer</surname>
<given-names>RL</given-names>
</name>
</person-group>. <article-title>The heart disease of Friedreich’s ataxia: a clinical and electrocardiographic study of 115 patients, with an analysis of serial electrocardiographic changes in 30 cases</article-title>. <source>Quarterly J Med</source>. <year>1983</year>;<volume>52</volume>(<issue>208</issue>):<fpage>489</fpage>–<lpage>502</lpage>.</citation>
</ref>
<ref id="bibr46-0883073812449382">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albano</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Nishioka</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Moyses</surname>
<given-names>RL</given-names>
</name>
<etal/>
</person-group>. <article-title>Friedreich’s ataxia: cardiac evaluation of 25 patients with clinical diagnosis and literature review</article-title>. <source>Arq Bras Cardiol</source>. <year>2002</year>;<volume>78</volume>(<issue>5</issue>):<fpage>444</fpage>–<lpage>451</lpage>.</citation>
</ref>
<ref id="bibr47-0883073812449382">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandolfo</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Friedreich ataxia</article-title>. <source>Semin Pediatr Neurol</source>. <year>2003</year>;<volume>10</volume>(<issue>3</issue>):<fpage>163</fpage>–<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr48-0883073812449382">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunt</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Chin</surname>
<given-names>MH</given-names>
</name>
<etal/>
</person-group>. <article-title>2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation</article-title>. <source>J Am Coll Cardiol</source>. <year>2009</year>;<volume>53</volume>(<issue>15</issue>):<fpage>e1</fpage>–<lpage>e90</lpage>.</citation>
</ref>
<ref id="bibr49-0883073812449382">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mancuso</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Orsucci</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Choub</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Siciliano</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Current and emerging treatment options in the management of Friedreich ataxia</article-title>. <source>Neuropsychiatr Dis Treat</source>. <year>2010</year>;<volume>6</volume>:<fpage>491</fpage>–<lpage>499</lpage>.</citation>
</ref>
<ref id="bibr50-0883073812449382">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Myers</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>RB</given-names>
</name>
<etal/>
</person-group>. <article-title>Antioxidant use in Friedreich ataxia</article-title>. <source>J Neurol Sci</source>. <year>2008</year>;<volume>267</volume>(<issue>1-2</issue>):<fpage>174</fpage>–<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr51-0883073812449382">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kemp</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mallam</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hares</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Witherick</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Scolding</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wilkins</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Mesenchymal stem cells restore frataxin expression and increase hydrogen peroxide scavenging enzymes in Friedreich ataxia fibroblasts</article-title>. <source>PLoS One</source>. <year>2011</year>;<volume>6</volume>(<issue>10</issue>):<fpage>e26098</fpage>.</citation>
</ref>
</ref-list>
</back>
</article>